摘要
目的:探讨蛭龙胶囊联合坎地沙坦对早期糖尿病肾病(DN)大鼠纤溶系统的影响。方法:采用高糖高脂饲料联合腹腔注射STZ的方法制备DN模型,分别以不同药物对模型鼠进行灌胃,采用酶联免疫法测定各组大鼠血浆tPA、PAI水平,观察肾脏病理形态学的变化。结果:各治疗组均能显著下调PAI(正常组19.58±3.12,模型组42.10±6.40,蛭龙胶囊组33.24±7.08,坎地沙坦组32.41±4.15,联合用药组28.08±4.94)含量及PAI/tPA值,上调tPA(正常组12.78±2.80,模型组6.32±1.46,蛭龙胶囊组7.63±1.85,坎地沙坦组7.87±1.66,联合用药组9.61±1.77)含量(P<0.01,P<0.05),减轻肾小球及肾小管损害,以联合用药组为著。结论:蛭龙胶囊联合坎地沙坦可以调节tPA与PAI的平衡,促进细胞外基质降解而延缓早期DN的进展。
Objective ：To investigate the effection of Zhilong capsule combined with candesartan on early diabetic nephropa- thy of rats in fibrinolytic system. Methods：Establish the early stage DN model by high sucrose, fat diet and intraperitoneal injection of STZ. Treated with Zhilong capsule and candesartan recipe for 8 weeks, measured the level of tPA, PAI serum by radioirnmunoassay , and observed the impaction of renal pathological morphology by optical microscopy. Results： All the groups of treatment can reduce the level of PAI（ normal control group 19.58 ± 3.12, model control group 42.10 ± 6.40, Zhilong capsule treatment group 33.24 ± 7.08, candesartan cilexetil treatment group 32.41 ± 4.15, combined treatment group 28.08 ± 4.94） content and PAI/tPA value, increase tPA（ normal control group 12.78 ± 2.80, model control group 6.32 ± 1.46, Zhilong capsule treatment group 7.63 ± 1.85, candesartan cilexetil treatment group 7.87 ± 1.66, combined treatment group 9.61 ± 1.77） content （P 〈 0. 01, P 〈 0.05 ）, and relieve the damage of glomerular and renal tubular in the diabetic nephropathy rats , and the result of Zhilong capsule combined with candesartan group is the most significantly. Conclusion：Zhilong capsule combined with candesartan can regulated the balance of tPA and PAI, promote the degradation of extracellular matrix and retard the progression of diabetic nephropathy in early stage.
出处
《中国中西医结合肾病杂志》
2013年第7期579-581,I0002,共4页
Chinese Journal of Integrated Traditional and Western Nephrology
基金
甘肃省中医药管理局项目(No.2007-GZK-28)
关键词
蛭龙胶囊
坎地沙坦
糖尿病肾病
纤溶系统
Zhilong capsule
Candesartan
Diabetic nephropathy
Fibrinolytic system
